Mubadala, CBC Group ink $680M deal for UCB’s neurology and allergy portfolio in China
Belgian pharma UCB is selling parts of its China business to Mubadala and CBC Group for $680 million. In addition to taking over UCB’s mature …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
